Why Yahoo-Tumblr Is...
Health Care: Drugs
Alexza Pharmaceuticals Inc. (ALXA: NASDAQ)
$4.45 0.06 | 1.37%
05/20/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -27.98M | -40.53M | -1.48M | -56.06M |
| Operating Gains/Losses | -415.00K | 0.00 | 79.00K | 43.00K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 10.00M | -10.00M | 1.41M | -1.41M |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 200.00K | -147.00K | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -1.46M | 822.00K | 76.00K | -2.22M |
| (Decrease) Increase In Other Current Liabilities | 559.00K | -498.00K | 3.92M | -2.72M |
| (Increase) Decrease In Other Working Capital | -6.83M | 3.97M | -1.17M | -11.19M |
| Other Non-Cash Items | 3.10M | 6.41M | 886.00K | 15.11M |
| Net Cash From Continuing Operations | -18.24M | -34.43M | 8.59M | -53.15M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -18.24M | -34.43M | 8.59M | -53.15M |
| Sale of Property, Plant & Equipment | 425.00K | 0.00 | 29.00K | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 2.00M | 54.04M | 41.94M | 34.59M |
| Purchases of Property, Plant & Equipment | -452.00K | -496.00K | -9.18M | -1.19M |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | -28.46M | -63.43M | -13.26M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 1.97M | 25.08M | -30.64M | 20.15M |
| Issuance of Debt | 0.00 | 0.00 | 14.81M | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 35.24M | 16.14M | 17.05M | 19.67M |
| Repayment of Long-Term Debt | -6.11M | -5.56M | -2.09M | -4.14M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -10.05M | 0.00 | -7.50M | 4.88M |
| Net Cash From Financing Activities | 19.08M | 10.58M | 22.27M | 20.42M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 2.81M | 1.23M | 221.00K | -12.59M |
Portfolios with ALXA
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorDrugs Facing FDA Approval i...
Latest ALXA Headlines from TheStreet
- Top Insider Trades: AEGR VVTV CCO ALXA 01.23.13 | 08:01 am
- 5 Stocks With Big Insider Buying 01.02.13 | 11:01 am
- 13 Biotech Stock Predictions for 2013 01.02.13 | 06:01 am
- Shorting Alexza Pharma On FDA's Adasuve Approval 12.19.12 | 07:12 am
- 6 Stocks On Winning Streaks Short Sellers Do Not Believe In 12.18.12 | 04:12 pm
- Stocks Socked Despite Upbeat China Numbers; Apple Falls 12.14.12 | 04:12 pm
- The Next Big Thing in Biotech: FDA Decisions
12.14.12 | 05:12 am - Alexza Pharma: Premium Selling Options Strategy 12.12.12 | 11:12 am
- Alexza Pharma: Run-Up Trade Into December's Approval Decisions 11.20.12 | 08:11 am
- 21 Most Volatile Biopharma Stocks Closing Out 2012 11.05.12 | 06:11 am
Press Releases for ALXA
- Peter W. Schineller Joins Alexza Pharmaceuticals As Senior Vice President And Chief Commercial Officer - PR Newswire 03.13.13 | 09:03 am
- Alexza To Report 2012 Year-End Financial Results On Tuesday, March 26, 2013 - PR Newswire 03.06.13 | 05:03 pm
- Alexza Pharmaceuticals' Corporate Presentation To Be Webcast At Three Upcoming Investor Conferences - PR Newswire 02.25.13 | 09:02 am
- Alexza Receives Marketing Authorization For ADASUVE® (Staccato® Loxapine) In The European Union - PR Newswire 02.21.13 | 09:02 am
- Alexza Pharmaceuticals Appoints J. Kevin Buchi To Its Board Of Directors - PR Newswire 01.03.13 | 09:01 am
- U.S. FDA Approves Alexza's ADASUVE® (loxapine) Inhalation Powder For The Acute Treatment Of Agitation Associated With Schizophrenia Or Bipolar I Disorder In Adults - PR Newswire 12.21.12 | 03:12 pm
- The CHMP Delivers A Positive Opinion Recommending Grant Of Marketing Authorization For ADASUVE® (Staccato® Loxapine) In The European Union - PR Newswire 12.14.12 | 08:12 am
- Alexza Pharmaceuticals Receives Updated Day 180 List Of Outstanding Issues For ADASUVE⢠(Staccato® Loxapine) MAA - PR Newswire 11.19.12 | 09:11 am
- Alexza Pharmaceuticals' Staccato® Technology Receives Frost & Sullivan Enabling Technology Award - PR Newswire 10.18.12 | 05:10 pm
- Alexza Announces Third Quarter 2012 Financial Results Teleconference And Webcast - PR Newswire 10.17.12 | 04:10 pm
Partner Headlines for ALXA
- After-Hours Earnings Report for May 14, 2013 : A, EXP, VIPS, PLAB, VOXX, ATHX, FENG, ALXA, TKMR, PRMW, QBAK, TXCC - NASDAQ 05.14.13 | 06:05 pm
- Alexza Pharmaceuticals Earnings Preview: Get Ahead of the Analysts - Wall St. Cheat Sheet 05.13.13 | 03:05 am
- Alexza Pharmaceuticals: Here’s What Investors Need to Know Before Earnings - Wall St. Cheat Sheet 05.09.13 | 02:05 am
- BioPharma Stock Movers For Wednesday, August 29 - Seeking Alpha 08.29.12 | 09:08 am
- 5 Pharmaceutical Companies With EMA Or MHRA Catalysts This Year - Seeking Alpha 08.28.12 | 09:08 am
- Good News for Alexza Pharma - Analyst Blog - NASDAQ 08.23.12 | 02:08 pm
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 07.20.12 | 09:07 am
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 07.18.12 | 09:07 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 07.16.12 | 09:07 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 07.10.12 | 09:07 am
